At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 390 enrolled
Drug / intervention
Alogliptin and insulin +2 moredrug
Likely dose
Alogliptin and insulin 12.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With Insulin in Subjects With Type 2 Diabetes
In Brief
A Phase 3 clinical trial evaluating Alogliptin and insulin and Insulin for Diabetes Mellitus. Completed, enrolled 390 participants across 60 sites in 16 countries.
Detailed Summary
The purpose of this study is to determine the efficacy and safety of alogliptin, once daily (QD), taken in combination with insulin for the treatment of Type 2 Diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus
CountriesArgentina, Australia, Brazil, Chile, Czechia, Germany, Guatemala, Hungary, India, Mexico, Netherlands, New Zealand, Peru, Poland, South Africa, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2006
First PostedFeb 2006
Primary CompletionMay 2007
TodayJul 2026
First PostedFeb 3, 2006
Enrollment StartFeb 1, 2006
Primary CompletionMay 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 20.4 years ago
Interventions
Alogliptin and insulindrug
Alogliptin 12.5 mg, tablets, orally, once daily and insulin for up to 26 weeks.
Alogliptin and insulindrug
Alogliptin 25 mg, tablets, orally, once daily and insulin for up to 26 weeks.
Insulindrug
Alogliptin placebo-matching tablets, orally, once daily and insulin for up to 26 weeks.